首页> 外文期刊>RSC Advances >Discovery of acylphloroglucinol-based meroterpenoid enantiomers as KSHV inhibitors from Hypericum japonicum
【24h】

Discovery of acylphloroglucinol-based meroterpenoid enantiomers as KSHV inhibitors from Hypericum japonicum

机译:丙烯酰氯氨基酚的梅特萜类映异构体作为来自金刚颗血清蛋白的KSHV抑制剂

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Kaposi's sarcoma associated herpesvirus (KSHV) has gained considerable attention as a type of carcinogenic pathogen. Recent research suggests that KSHV has participated in the pathogenesis of Kaposi's sarcoma-related malignant neoplastic diseases. Viral lytic infection might be pivotal for the etiopathogenesis of KSHV-induced diseases; however, most clinical KSHV lytic replication inhibitors like ganciclovir, nelfinavir, or cidofovir do not restrain virus replication effectively enough to achieve clinical efficacy. In our continued pharmaceutical studies on Chinese herbal medicines, new acylphloroglucinol-based meroterpenoid enantiomers have been discovered from Hypericum japonicum. Most of these metabolites have potential inhibitory activities that target KSHV lytic replication. Amongst these analogues, compounds 1a and 1b possess an unreported ring system cyclopenta[b]chromene. Compounds la with 4a exhibit stronger inhibitory activities towards the lytic replication of KSHV in Vero cells. In addition, 1a and 4a have IC50 values of 8.30 and 4.90 mu M and selectivity indexes of 23.49 and 25.70, respectively. Qualitative and quantitative SAR and molecular docking studies for acylphloroglucinol-based meroterpenoids with regard to anti-KSHV activity were conducted. An explanation for the variation in the activity and selectivity indexes was proposed in accordance with the predicted binding pose found with molecular docking to a putative target, thymidylate synthase (kTS). Compounds 1a and 4a have potential for further development and optimization of their anti-KSHV activities which could lead to new candidate drugs.
机译:Kaposi的肉瘤相关的Herpesvirus(KSHV)作为一种致癌病原体的态度很大。最近的研究表明,KSHV参与了Kaposi与肉瘤相关恶性肿瘤疾病的发病机制。病毒含裂解感染可能是KSHV诱导疾病的病因发生的关键;然而,大多数临床KSHV裂解抑制剂,如Ganciclovir,Nelfinavir,或Cidofovir,不抑制病毒复制,以达到临床疗效。在我们对中草药的持续药物研究中,已发现新的丙烯酰氯氨基酚的丙醇丙二醇映异构体已从金丝桃属粳稻发现。大多数这些代谢物具有潜在的抑制性能,可靶向KSHV裂解复制。在这些类似物中,化合物1a和1b具有未报告的环系统环戊基[b]铬。具有4A的化合物La表现出较强烈的抑制活动,朝鲜KSHV在VERO细胞中复制。另外,图1A和4A的IC 50值为8.30和4.90μm,分别为23.49和25.70的选择性指数。进行了关于抗KSHV活性的丙烯酰氯氨基酚的丙烯酸丙烯酚的定性和定量SAR和分子对接研究。根据用分子对接至推定靶,胸苷合酶(KTS)的预测结合姿势提出了对活性和选择性指标的变化的说明。化合物1A和4A具有进一步发展和优化其可能导致新候选药物的抗KSHV活动的潜力。

著录项

  • 来源
    《RSC Advances》 |2018年第43期|共9页
  • 作者单位

    Hubei Univ Natl &

    Local Joint Engn Res Ctr High Throughput D Sch Life Sci Hubei Key Lab Biotechnol Chinese Tradit Med Wuhan 430062 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Cent Hosp Wuhan Wuhan 430014 Hubei Peoples R China;

    Peking Univ Sch Pharmaceut Sci State Key Lab Nat &

    Biomimet Drugs Beijing 100191 Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

    Peking Univ Sch Pharmaceut Sci State Key Lab Nat &

    Biomimet Drugs Beijing 100191 Peoples R China;

    Hubei Univ Natl &

    Local Joint Engn Res Ctr High Throughput D Sch Life Sci Hubei Key Lab Biotechnol Chinese Tradit Med Wuhan 430062 Hubei Peoples R China;

    Huazhong Univ Sci &

    Technol Tongji Med Coll Sch Pharm Hubei Key Lab Nat Med Chem &

    Resource Evaluat Wuhan 430030 Hubei Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号